Biomarker Core

生物标志物核心

• 批准号: 10409747
• 负责人: TONY WYSS-CORAY
• 金额: $ 40.06万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10409747
• 关键词: Algorithmic Analysis; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer’s disease biomarker; Amyloid beta-42; Amyloid beta-Protein; Bioinformatics; Biological Assay; Biological Markers; Biology; Blood; Blood Cells; Cardiovascular Diseases; Cells; Clinical; Clinical Management; Collection; Cytometry; DNA; Data; Data Analyses; Data Set; Databases; Dementia; Detection; Development; Diabetes Mellitus; Disease; Equipment and supply inventories; Feces; Fibroblasts; Gene Expression; Genetic; Glial Fibrillary Acidic Protein; Goals; Human; Image; Immune; Individual; Information Dissemination; Lead; Light; Liquid substance; Measurement; Measures; Methods; Mission; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Parkinson' s Dementia; Participant; Pathologic Processes; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Populations at Risk; Process; Proteome; Proteomics; Publishing; Quality Control; RNA; Reproducibility; Research; Research Personnel; Sampling; Sensitivity and Specificity; Signal Transduction; Skin; Source; Standardization; T-Cell Receptor; Technology; Time; Tissues; Training Support; Work; analysis pipeline; base; bioinformatics tool; biomarker performance; data management; data sharing; experience; genetic variant; gut microbiome; imaging modality; member; microbiome; molecular marker; multiple omics; neurofilament; neuropathology; next generation; novel; novel marker; novel therapeutics; public database; receptor expression; research study; skin microbiome; stool sample; tau Proteins; tau-1; tissue biomarkers; tool; transcriptome; transcriptome sequencing; transcriptomics; web portal; whole genome

1. SUMMARY (Biomarker Core) Biomarkers have enormous value for the detection, management, and treatment of disease, but also for the development of novel therapeutics. The utility of biomarkers is most evident in the management of cardiovascular disease and diabetes, but biomarkers, especially predictive, easily obtainable ones, are still largely absent with respect to neurodegenerative diseases. The best fluid biomarkers currently available for Alzheimer’s disease (AD) include; Aβ, tau, and neurofilament in CSF, a biofluid which is difficult to collect in healthy, at-risk populations or on a repeated basis. Other biomarkers for AD include imaging modalities which are often very expensive or have low sensitivity and specificity at the individual level. The members of this core have considerable experience in unbiased multi-omic screens and data analysis and, over the years, have published numerous studies towards developing new biomarkers for neurodegenerative and other diseases. Enabled by the current ADRC, the core leaders and collaborators have used biospecimens from Stanford ADRC participants and generated extensive preliminary data with unbiased deep immune phenotyping, proteomics, and transcriptomics of human CSF resident cells, and discovered novel Parkinson's disease (PD) biomarkers. Based on this expertise, the mission of this Biomarker Core is to facilitate the discovery of novel biomarkers for AD and PD, as well as new biology underlying the pathological processes that lead to dementia in line with the core mission of the NAPA. This will be achieved by pursuing the collection of genetic and molecular measurements from a broad source of tissues from ADRC participants; the processing and dissemination of this information in useable formats through web portals and other means (i.e., “Deep Phenotyping Database”); the analysis and bioinformatics integration of the collected information with clinical and imaging data, as well as information from public databases; and the development and dissemination of new data analysis algorithms and pipelines.

1。摘要（生物标志物核心） 生物标志物对于疾病的检测，管理和治疗具有巨大的价值，也对 新疗法的发展。生物标志物的效用是管理 心血管疾病和糖尿病，但生物标志物，尤其是可预测的，易于获得的疾病，仍然是 在神经退行性疾病方面，很大程度上没有。目前可用于的最好的流体生物标志物 阿尔茨海默氏病（AD）包括； CSF中的Aβ，tau和神经丝是一种生物流体，很难收集 健康的，处于危险的人群或重复的基础。其他用于广告的生物标志物包括成像方式 通常非常昂贵或在个人层面上具有低灵敏度和特异性。这个核心的成员 在公正的多摩尼克屏幕和数据分析方面具有丰富的经验，多年来 发表了许多研究，用于开发用于神经退行性和其他疾病的新生物标志物。 由当前ADRC启用，核心领导者和合作者使用了斯坦福大学的生物测量 ADRC参与者并产生了广泛的初步数据，并具有无偏的深度免疫表型， 蛋白质组学和人类脑脊液居民细胞的转录组学，并发现了新颖的帕金森氏病（PD） 生物标志物。基于这种专业知识，这种生物标志物核心的使命是促进新颖的发现 AD和PD的生物标志物以及导致痴呆症的病理过程的新生物学 符合纳帕的核心任务。这将通过追求遗传和 来自ADRC参与者的广泛组织来源的分子测量；处理和 通过Web门户和其他方式以可用格式传播此信息（即“深处） 表型数据库”）;收集的信息与临床的分析和生物信息学集成 和成像数据以及公共数据库中的信息；以及的发展和传播 新的数据分析算法和管道。